TOP TEN perturbations for 39148_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39148_s_at
Selected probe(set): 208861_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39148_s_at (208861_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-4.7142878Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.8820162Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.140129Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
polyamide study 1 (match) / vehicle (medium) treated A549 cell sample
Relative Expression (log2-ratio):-2.8260956Number of Samples:3 / 3
| Experimental | polyamide study 1 (match) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | vehicle (medium) treated A549 cell sample |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. Samples were taken after additional 56 hours. |
polyamide study 1 (match) / mifepristone study 4
Relative Expression (log2-ratio):-2.809472Number of Samples:3 / 3
| Experimental | polyamide study 1 (match) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | mifepristone study 4 |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3µM of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code: |
zalypsis study 1 / untreated MM1S cell sample
Relative Expression (log2-ratio):-2.7499676Number of Samples:2 / 2
| Experimental | zalypsis study 1 |
| MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated MM1S cell sample |
| MM1S multiple myeloma cells untreated. |
polyamide study 1 (match) / dexamethasone study 8
Relative Expression (log2-ratio):-2.7042847Number of Samples:3 / 3
| Experimental | polyamide study 1 (match) |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. | |
| Control | dexamethasone study 8 |
| Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:, , , , , , , , , , |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.6532955Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):2.549779Number of Samples:4 / 2
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.530532Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |